Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) EPS (Basic) (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed EPS (Basic) for 3 consecutive years, with -$0.63 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 33.68% to -$0.63 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.73 through Dec 2025, up 33.46% year-over-year, with the annual reading at -$1.72 for FY2025, 32.81% up from the prior year.
  • EPS (Basic) hit -$0.63 in Q4 2025 for NewAmsterdam Pharma, down from -$0.61 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.15 in Q2 2025 to a low of -$1.06 in Q1 2024.
  • Historically, EPS (Basic) has averaged -$0.54 across 3 years, with a median of -$0.54 in 2023.
  • Biggest five-year swings in EPS (Basic): soared 68.42% in 2024 and later tumbled 238.89% in 2025.
  • Year by year, EPS (Basic) stood at -$0.6 in 2023, then tumbled by 58.33% to -$0.95 in 2024, then skyrocketed by 33.68% to -$0.63 in 2025.
  • Business Quant data shows EPS (Basic) for NAMS at -$0.63 in Q4 2025, -$0.61 in Q3 2025, and -$0.15 in Q2 2025.